11 days ago
INSM
AnalystsNicole GerminoNicole Germino's Stock Forecasts
AnalystsNicole Germino
Sectors:
Industries:
Analyst Ranking
Top 15%
#741 out of 4995 analysts
Average Return
+30.04%
Win Rate
60%15 out of 25
Risk vs Reward
Poor
Good
Nicole Germino's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Insmed IncINSM | +181.92% | $25.27 | $71.24 | 2024-04-22 - 2025-04-22 | Strong Buy |
Insmed IncINSM | +167.81% | $25.10 | $67.22 | 2024-05-15 - 2025-05-15 | Strong Buy |
Y Mabs Therapeutics IncYMAB | +134.34% | $3.64 | $8.53 | 2025-05-13 - 2025-08-22 | Strong Buy |
Perspective Therapeutics IncCATX | +104.44% | $1.80 | $3.68 | 2025-04-06 - 2025-08-22 | Strong Buy |
Point Biopharma Global IncPNT | +102.95% | $6.11 | $12.40 | 2022-11-14 - 2023-10-04 | Strong Buy |
Nicole Germino Analyst Color
Get additional color on Nicole Germino's coverage of popular stocks
6 months ago
INSM
10 months ago
INSM
Nicole Germino's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Insmed IncINSM | 9 | Strong Buy | $139.00 | +5.40% | Maintains | 11 days ago |
Y Mabs Therapeutics IncYMAB | 3 | Strong Buy | $14.00 | +64.13% | Maintains | 3 months ago |
Perspective Therapeutics IncCATX | 3 | Strong Buy | $8.00 | +117.39% | Maintains | 3 months ago |
Sangamo Therapeutics IncSGMO | 4 | Strong Buy | $5.00 | +753.24% | Maintains | 7 months ago |
Fusion Pharmaceuticals IncFUSN | 3 | Hold | $21.00 | N/A | Downgrades | a year ago |
Point Biopharma Global IncPNT | 3 | Hold | $12.50 | N/A | Downgrades | 2 years ago |
Assembly Biosciences IncASMB | 3 | Hold | $24.00 | N/A | Downgrades | 3 years ago |
Forte Biosciences IncFBRX | 1 | Strong Buy | $1,750.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.